This observational study, sponsored by Nanjing First Hospital, aims to identify biomarkers that predict clopidogrel resistance in ischemic stroke patients. The potential commercial implications are significant, as clopidogrel is widely used for secondary stroke prevention. If successful, the study could lead to the development of a biomarker panel that enhances patient stratification and treatment efficacy, thereby improving clinical outcomes and reducing healthcare costs. The market for stroke management and antiplatelet therapies is substantial, with ongoing competition from emerging therapies and diagnostics. Companies focusing on personalized medicine and biomarker development may find strategic partnerships or acquisition opportunities in this space.